Rev Med Inst Mex Seguro Soc. 2023 Sep 18;61(Suppl 2):S155-S160.
ABSTRACT
BACKGROUND: Coronavirus disease 2019 (COVID-19) can cause cardiac injury, probably associated with myocarditis and ischemia induced by the infection. Myocardial damage leads to the liberation of proinflammatory cytokines and to the activation of autoimmune adaptive mechanisms through molecular limitation.
OBJECTIVE: To assess mortality associated with myocardial damage in hospitalized patients with COVID-19 confirmed by troponin I measurement.
MATERIAL AND METHODS: Case-control study nested in a cohort of patients of a third-level hospital. Descriptive statistics were used to characterize the population. Qualitative variables were expressed as proportions and ranges, quantitative variables as means and standard deviation. Fisher’s exact test was used to compare mortality between patients with and without myocardial damage. A p value < 0.05 was considered significant.
RESULTS: From June 2020 to August 2020, 28 patients who met the selection criteria were enrolled, out of which 15 had no myocardial damage and 13 had myocardial damage assessed by serum troponin measurement. A strong association was found between mortality and the presence of myocardial damage, since mortality was 20% (3/15) among patients without myocardial damage and 92.3% (12/13) among those with myocardial damage (Fisher’s exact test, p < 0.005).
CONCLUSION: Mortality in patients with COVID-19 is associated with myocardial damage assessed by troponin I measurement.
PMID:38011615
